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Abstract
Background: As part of the Houston Vanguard study, a subset of 10 patients randomized to
receive IL-2 therapy were compared to 4 patients randomized to not receive IL-2, for markers of
T cell activation and death during the first three cycles of IL-2. All patients were treated with
combination antiretroviral therapy (ART) and were virally suppressed. The purpose of the study
was to examine the role of CD8+ T cell death in responses to ART and IL-2 therapy.
Methods: Lymphocytes were examined at Day 0, 5 and 30 days during three cycles of IL-2 therapy.
CD25, CD38, HLA-DR expression and annexin (cell death) were examined on CD4 and CD8
subpopulations. Follow up studies examined CD4 levels and CD4:CD8 reconstitution after 6 years
using both univariant and multivariate analyses.
Results: Human lymphocytes responded to IL-2 therapy by upregulation of CD25 on CD4+ T cells,
leading to an increase in CD4 cell counts. CD8+ T cells did not increase CD25 expression, but
upregulated activation antigens (CD38 and DR) and had increased death. At baseline, 7 of the 14
patients had high CD8+ T cell apoptosis (mean 17.0% ± 6.0). We did an exploratory analysis of
immune status after six years, and found that baseline CD8+ T cell apoptosis was correlated with
CD4 cell count gain beginning two years post enrollment. Patients with low levels of CD8+ T cell
apoptosis at baseline (mean 2.2% ± 2.1) had significantly higher CD4 cell counts and more
normalized CD4:CD8 ratios than patients with high CD8+ T cell apoptosis (mean CD4 cell counts
1,209 ± 164 vs 754 ± 320 cells/mm3; CD4:CD8 ratios 1.55 vs. 0.70, respectively).
Conclusion: We postulate that CD8+ T cell apoptosis may reflect inherent activation status, which
continues in some patients even though viral replication is suppressed which influences the ability
of CD4+ T cells to rebound. Levels of CD8+ T cell apoptosis may therefore be an independent
predictor of immune status, which should be shown in a prospective study.
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Background
IL-2 therapy leads to dose-dependent, sustained CD4 cell
count increases in most HIV-infected patients treated with
antiretroviral therapy (ART) [1,2]. Early increases in both
CD4+ and CD8+ T cell subsets occurs, but only the CD4+ T
cell population maintains higher numbers over the long-
term [3,4]. The mechanism may involve the ability of
CD4+ T cells to better upregulate the high affinity IL-2
receptor, CD25 or it may involve preferential survival of
CD4+ T cells. Recent data suggests that the expansion of
CD25 expressing cells after IL-2 administration is associ-
ated with less proliferation of T cells in the long-term (12
months) as measured by both Ki67 expression [3,4] and
after in vivo labeling of DNA [4]. It is suggested that IL-2
actually allows CD4 expansion to be maintained by
decreasing immune activation levels. One possible expla-
nation is that IL-2 causes the expansion of regulatory
CD4+ CD25+ T cells, which might limit subsequent CD4 T
cell activation [5].
Other predictors of the amount of CD4 restoration after
IL-2 include the CD4 nadir and the age of the patient
[6,7]. The lower the CD4 nadir, the fewer numbers of
CD4+ T cells return after IL-2 therapy. Likewise, the older
the IL-2 treated patient, the less likely they are to respond
well to IL-2, especially after three cycles [7]. Non-respond-
ers to IL-2 therapy also tend to have more T cell prolifera-
tion at baseline, as well as reduced numbers of recent
thymic emigrants, suggesting increased turnover of the
peripheral T cell pool [6,7].
In another study, a predictor of the amount of CD4+  T cell
return after IL-2 therapy was being non-white; this group
of individuals had almost a 200 cells/mm3 larger increase
in CD4 cell counts than the white group studied from a
cohort of more than 250 patients [6].
Another feature of HIV pathogenesis that might influence
T cell normalization after immune reconstitution is the
increased cell death of both CD4+ and CD8+ T cells that is
commonly seen in HIV-infected patients. Increased CD4+
T cell death could be due to HIV infection directly or
bystander CD4+ T cells may die via multiple mechanisms
(8–10). CD8+ T cell death is likely due to increased activa-
tion [11-13]. In terms of reduction of lymphocytic apop-
tosis after ART, several studies show a reduction; however,
apoptosis levels do not return to normal levels, but
remain elevated in most [14-16].
One study showed that the levels of T cell apoptosis, espe-
cially CD8+ T cell apoptosis, was associated with recovery
of CD4+ T cell numbers after ART, so that higher levels of
CD8+ T cell apoptosis was associated with fewer CD4+ T
cells after therapy [17]. This is consistent with our own
cross-sectional observation that patients with fewer CD4+
T cells also had more CD8+ T cell apoptosis, whether or
not they were on ART therapy [18]. Another study has
shown that the amount of CD4+ T cell apoptosis was
reduced after four weeks with or without IL-2 therapy, but
reduction of CD8+ T cell apoptosis levels took 24 weeks to
develop [19]. However, levels of lymphocytic apoptosis
were still higher than in controls and was similarly ele-
vated in both ART treated and ART plus IL-2 treated
patients [19,20]. When lymph nodes were examined for
levels of T cell death before and after ART, low levels of
CD8+ T cell apoptosis remained after ART, which were
reflective of continuing low levels of viral replication [21].
The present Houston Vanguard sub-study examines a
small group of subcutaneously IL-2 (scIL-2) treated
patients. Patients were randomized from October 1998 to
May 1999. An exploratory analysis of immunologic status
was assessed an average of six years after randomization.
We found that, in this small group of patients, the level of
spontaneous CD8+ T cell apoptosis at baseline before
commencing scIL-2 therapy was associated with both
CD4 cell counts as well as CD4:CD8 ratio normalization
after six years. These differences in T cell numbers based
on initial CD8+ T cell apoptosis levels appeared after two
years of scIL-2 therapy and were maintained until the cur-
rent analysis.
Methods
Study population
To participate in the Houston Vanguard study, subjects
had to be at least 18 years old, have documented HIV-1
infection and a CD4 cell count ≥ 350 cells/mm3 at screen-
ing. The Karnofsky performance status had to be ≥ 80 and
the patients had to be receiving antiretroviral therapy for
at least 7 days prior to starting scIL-2 therapy. Women of
childbearing potential were required to have a negative
pregnancy test before initiation of scIL-2 therapy. At base-
line, all but one of the individuals had plasma HIV RNA
levels below 500 copies/mL. That single individual had a
viral load of 2,007 copies/mL. The main exclusion criteria
for this study included any concurrent or prior history of
AIDS-defining illnesses, malignancy requiring systemic
therapy within the prior 5 years, concomitant use of sys-
temic corticosteroids, chemotherapy or experimental
cytotoxic drugs, or current or prior history of autoimmune
and/or inflammatory diseases and breastfeeding. This
study was approved by the institutional review board
(IRB) at The University of Texas Health Science Center at
Houston and the National Institute of Allergy and Infec-
tious Disease (NIAID) IRB. All subjects provided written
informed consent.
Trial design
The Houston Vanguard study was an open-label, rand-
omized trial designed with a target sample size of 72 sub-Journal of Translational Medicine 2007, 5:9 http://www.translational-medicine.com/content/5/1/9
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jects with CD4 cell count change from baseline as the
primary endpoint. Subjects were sequentially randomized
to three groups of 24 (12 in each treatment group, scIL-2
or antiretroviral alone). The first group of 24 subjects
received 1.5 Million International units (MIU) per dose of
scIL-2 plus antiretroviral therapy or antiretroviral therapy
alone (control); the second group of 24 subjects was ran-
domized to 4.5 MIU scIL-2 or control; and the third group
was randomized to 7.5 MIU of scIL-2 or control. For the
purpose of this immunology sub-study of the Houston
Vanguard, consecutive patients who volunteered to partic-
ipate in the sub-study were enrolled: five patients from the
1.5 MIU per dose cohort (low dose), five patients from the
7.5 MIU per dose cohort (high dose) and four from the no
IL-2 cohort (control group).
scIL-2 treatment
Subcutaneous IL-2 (aldesleukin [Proleukin]; Chiron,
Emeryville, CA) was administered for 5 days every 8 weeks
for a minimum of three cycles in addition to continued
antiretroviral therapy. Dosing with scIL-2 was begun at
1.5 MIU. This dose was escalated to 4.5 MIU and then to
7.5 MIU when at least 9 of the 12 subjects had completed
all doses of the first cycle with scIL-2 at a lower dose level
in the absence of dose-limiting toxicities. Dose reductions
of scIL-2 were allowed for dose-limiting toxicities defined
as grade IV toxicities (as defined in the National Institutes
of Health, Division of AIDS Toxicity Table for Grading
Adverse Events), investigator's assessment or subject toler-
ance.
After completion of three cycles, subjects were enrolled in
an extension phase (months 6 to 12) and, thereafter,
rolled-over into the ESPRIT study (Evaluation of subcuta-
neous Proleukin® in a Randomized International Trial).
Additional cycles of scIL-2 were encouraged to maintain
CD4 cell counts more than twice baseline or greater than
1,000 cells/mm3. For subjects randomized to 1.5 and 4.5
MIU, dose escalation was allowed by increments of 1.5
MIU per dose up to a maximum of 7.5 MIU. Subjects
receiving less than 4.5 MIU were permitted to dose esca-
late by increments of 1.5 to 3.0 MIU upon the investiga-
tor's discretion. Dosage could be reduced by 1.5 MIU
decrements (to a minimum dose of 1.5 MIU) if the
assigned dose was not tolerated. During the extension
phase and roll-over ESPRIT no control subjects were
treated with scIL-2 at any dose. The cumulative amount of
IL-2 given to the 10 IL-2 treated patients in this study
ranged between 165–570 MIU, with a mean of 302 ± 132.
Follow-up studies
Of the 14 originally enrolled in the study, 11 were still fol-
lowed by Year 6. One patient with low CD8+ T cell apop-
tosis at baseline dropped out before Year 2, and two of the
non-IL-2 patients withdrew consent, one before Year 1
and one before Year 3. Both of these patients had high lev-
els of CD8+ T cell apoptosis at baseline.
Measurements of viral load/Lymphocyte aubsets
Plasma HIV RNA levels were quantified by branched DNA
signal amplification assay (Quantiplex; Chiron Emery-
ville, CA, Version 2.0, lower limit of detection 500 copies/
mL; and 3.0, lower limit of sensitivity 50 copies/mL). CD4
and CD8 counts were done by commercial flow cytometry
laboratories using CAP defined criteria.
Measurements of activation and death on lymphocyte 
subpopulations
Peripheral blood was separated using Ficoll gradients. The
cells were washed in PBS, counted and then stained for
cell surface markers and Annexin V to determine levels of
apoptotic cells. CD4, CD8, CD25, CD38, and DR anti-
bodies were purchased from BD Pharmingen (San Jose,
CA) and Annexin V was obtained from Biosource Interna-
tional (Camarillo, CA). The cells were analyzed using a
Beckman Coulter XL2 flow cytometer. Twenty-thousand
events were collected, gated on "viable" light scatter, and
fluorescence distributions collected and analyzed and
expressed as percentages or mean fluorescence intensity
[18].
Statistical analysis
Group means and standard deviations of study variables:
CD4, CD8, and CD4:CD8 ratios were obtained for both
low and high annexin groups. Tests for normality were
performed. Normally distributed data were analyzed
using the t-test and one way repeated measures analysis of
variance. A difference of p < 0.05 was considered signifi-
cant. For missing data, the last value carried forward
(LVCF) principle was applied to the analyses. A multivar-
iate analysis of the data was also performed using general-
izing estimating equations (GEE) a technique appropriate
for longitudinal data with a small number of subjects
[22]. Variables entered, separately at first, in the models as
covariates of annexin included age at randomization, age
at diagnosis and race. CD4 nadir was not included
because it is a component of the outcome variables (CD4
T cell count and CD4: CD8 ratio). Age was included as a
continuous variable. Race was dichotomized to black and
non-black.
Results
Initial studies
Initial studies conducted after randomization examined
five scIL-2 treated patients at high dose (7.5 MIU per dose)
and five on low dose (1.5 MIU per dose) for three cycles
of scIL-2 over a six month period. These groups were com-
pared to four patients treated with ART who did not
receive scIL-2 therapy (controls). Results show that the
absolute CD4 cell counts increased in all three groups andJournal of Translational Medicine 2007, 5:9 http://www.translational-medicine.com/content/5/1/9
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that the ending CD4:CD8 ratios were significantly differ-
ent between groups (Table 1). Those receiving the highest
dose of scIL-2 had the biggest increase in the CD4:CD8
ratio.
Similar to what others have observed, there was an
increase of CD25, the high affinity IL-2 receptor, on the
CD4+ T cells five days after scIL-2 therapy, as shown in Fig-
ure 1. The percentages and numbers of CD25+ CD4+ T
cells before and after three cycles of scIL-2 therapy in the
three groups are shown in Tables 2 and 3. Such an increase
in CD25 expressing cells was not observed for CD8+ T cells
(Figure 2). Rather, at Day 5 there was a sharp increase in
CD8+ CD38+ DR+ bright cells, as shown in Figure 3. The
high levels of these cells returned to baseline by Day 30 of
each cycle.
Next, we examined whether cells were dying at increased
levels both before and after IL-2 therapy by Annexin V
staining. At baseline, 7 patients had high levels of CD8+ T
cell apoptosis (17.0% ± 6.0) and 7 patients had low levels
CD8+ T cell apoptosis (2.2% ± 2.1). Four and 6 patients
from each group, respectively, received scIL-2. After five
days of scIL-2 therapy there was an increase in CD8 apop-
tosis which mirrored the amount of the CD38+ DR+
increase, as shown in a representative patient in Figure 4.
Very little increase in CD4+ T cell death was seen. We also
observed increases in CD38 and DR expression on the
CD4+ T cells at 5 days (data not shown). The levels of
CD38 and DR returned to normal on both CD4+ and
CD8+ T cells after each cycle. There was variability in the
amounts of cell death and CD38 and DR increases over
the cycles, depending on the person and cycle number
with no discernible pattern. In sum, our initial data is
characteristic of the data in a number of published papers
with larger groups of patients, except that we saw little
CD4+ T cell death [7,23].
Follow-up studies
Six years after our initial study, we examined the patients
for their immune status using an exploratory analysis. We
compared their CD4 and CD8 cell counts and the
CD4:CD8 ratios to their baseline parameters. At baseline,
only 3 of the 14 patients had CD4:CD8 ratios over 1; five
patients had ratios below 0.5. Examination after six years
showed that 9 of 12 patients had CD4:CD8 ratios over 1
and only 2 patients had ratios below 0.5.
We next examined possible factors associated with good
responses and poor responses to ART in this 6-year period,
independently of scIL-2 administration. We found a cor-
relation between the percentage of Annexin V+ CD8+ T
cells at baseline and the final CD4 cell count and
CD4:CD8 ratio, which indicates the extent of T cell nor-
malization. Patients with high levels of CD8+ T cell apop-
tosis at baseline (mean 17.0% ± 6.0) did not normalize
their CD4 cell counts or CD4:CD8 ratios after six years of
follow-up; whereas, patients with low levels of CD8+ T cell
apoptosis (mean 2.2% ± 2.1) normalized their CD4 cell
counts and CD4:CD8 ratio. The mean CD4 cell counts
were 1,209 ± 164 vs 754 ± 320 cells/mm3  and the
CD4:CD8 ratios 1.55 vs. 0.70, for the low and high base-
line CD8+  T cell apoptosis level groups, respectively
(Tables 4 and 5).
To determine when during the follow-up period this effect
occurred, we examined CD4:CD8 ratios in the high and
low CD8+ T cell apoptosis groups over time and found the
results shown in Figure 5. By two years of follow-up, the
high and low CD8+ T cell Annexin V positive groups were
separated by differences in their CD4:CD8 ratios, which
were differentially maintained to the present.
We also examined this small group of patients for predic-
tors of CD4 cell count increase and CD4:CD8 ratio nor-
malization. A summary is shown in Table 6. There were
no differences in age, sex, duration of HIV infection or co-
infections with HBV or HCV. There was a trend of lower
CD4 nadir among patients in the high vs. low CD8 apop-
tosis groups (  = 299 ± 144 vs. 178 ± 93, respectively;
median was 384 versus 203), but this difference was not
statistically significant.
Examination of the ethnic distribution of the two groups
revealed that there were one white, two Hispanics and
four Blacks in the low apoptosis group and two whites
and 5 Hispanics in the high apoptosis group. Thus, in this
small sample, all four Blacks recovered CD4 numbers bet-
ter after six years. Similar results were suggested in a previ-
x
Table 1: Increase in CD4 Cell Counts and CD4:CD8 Ratio After 3 scIL-3 Cycles.
scIL-2 Dosage Change in CD4 Number Increase in Ratio*
7.5 MIU(n = 4) 863 ± 434 0.88 ± 0.15
1.5 MIU(n = 5) 554 ± 458 0.53 ± 0.09
Control (n = 3) 442 ± 284 0.23 ± 0.14
* Day 65 in treated and week 24 in controls.
All different from each other (p = < 0.01). All patients increased their CD4:CD8 ratio, with the high dose IL-2 patients responding best. There is 
one missing endpoint in the high dosage at Day 65 and one in the group that received no IL-2 at 24 weeks.Journal of Translational Medicine 2007, 5:9 http://www.translational-medicine.com/content/5/1/9
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ous much larger study, which examined non-whites, most
of which were Black (70%) [6].
We next used GEE modeling to exam the outcomes over
time. Baseline annexin had a significant inverse relation-
ship with CD4 T cell count and ratio over time (p ≥ 0.02).
When age at randomization was entered into the model,
baseline annexin remained a significant predictor of both
CD4 T cell count over time (p ≥ 0.04) and CD4:CD8 ratio
(p ≥ .0.05). A similar finding occurred for age at HIV diag-
nosis, so that baseline annexin remained a significant pre-
dictor of CD4+ cell count over time (p ≥ 0.03) and
CD4:CD8 ratio (p ≥ .0.04). When race was entered into
the model, annexin was no longer independently related
to CD4 T cell and CD4:CD8 ratio over time. When
annexin, age and race were entered into the model, age at
diagnosis was significant predictor of CD4 T cell number
over time (p ≥ 0.03). Thus, this data is similar to previ-
ously reported trends with age as a predictor.
Discussion
These results, in a small group of scIL-2 treated, virally
suppressed HIV-infected patients suggest that the amount
of CD8 cellular death at baseline may correlate with the
ability to restore CD4 cell counts and CD4:CD8 ratios
after immune reconstitution involving ART with or with-
out additional scIL-2 therapy. These differences were
detectable after two years of study enrollment. Increased
CD8+ T cell apoptosis was a characteristic of about 70% of
previously studied patients where we found a negative
correlation between high CD8+ T cell apoptosis and low
CD4+ T cell percentages [18]. Others have also suggested
that the activation level of CD8+ T cells in HIV-infected
patients is an independent predictor of immune status,
separable from viral load and CD4 cell count [24,25]. Our
data in virally suppressed patients suggest that levels of
CD8+ T cell apoptosis also may independently predict
response to therapies, including scIL-2, by not only
increasing the absolute number CD4 cells, but perhaps by
regulating the levels of CD8+ T cell expansion.
The role of lymphocytic apoptosis in the response to ART
with or without IL-2 has been studied by several groups.
Most suggest apoptosis levels of both CD4+ and CD8+ T
cells tend to be reduced after ART (14–16). However, in
multiple studies, the levels of apoptosis still remains
higher than in controls, which likely indicates the pres-
ence of continued immune activation which was previ-
ously demonstrated in the lymph nodes [21]. IL-2 therapy
seems to have little effect on apoptosis levels in the long-
term. Preferential apoptosis of activated CD8+ T cells was
also seen by another group at 5 days post scIL-2 therapy
similar to our observations [23]. However, there was little
difference in spontaneous CD8+ T cell apoptosis levels
with time, suggesting that IL-2 did not change the inher-
ent level of CD8+ T cell apoptosis.
The work that most closely approximates the work
reported here followed 17 patients during the first 2–3
years of ART and showed that lymphocyte apoptosis was
reduced most in those who had the best response to ther-
apy [26]. Although the beginning levels of apoptosis
appear different between good responders and poor
responders in that study, the authors did not note that this
might be an important variable for the outcome. They do
show a negative correlation between the percentage of
Annexin V+ CD8+ T Cells and CD4+ T cells over two years
of ART therapy. Another difference in our work is that the
patients were already virally suppressed when baseline
apoptosis was measured. Our data, with a small group of
Table 3: Increases in CD4+ T Cells after IL-2 Therapy; Numbers of CD25+ CD4+ T Cells
scIL-2 dose Baseline After 3 Cycles Change
7.5 MIU 16.6 ± 13.0 315.4 ± 196.7 299 ± 199
1.5 MIU 12.8 ± 13.6 110.6 ± 103.9 98 ± 111
Control 22.3 ± 15.6 52.3 ± 15.3 30 ± 23
Numbers of CD25+ CD4+ T cells at baseline and after 3 cycles of scIL-2 therapy (week 24). The high dose IL-2 produced the greatest increase in 
CD25 numbers after scIL-2 administration. The high group had 4, the low group has 5 and none had 3.
Table 2: Increases in CD4+ CD25+ T Cells after IL-2 Therapy; Percentages of CD25+ CD4+ T Cells
scIL-2 dose Baseline After 3 Cycles Change
7.5 MIU 1.0 ± 0.7 10.7 ± 6.7 9.7 ± 6.7
1.5 MIU 0.9 ± 0.6 3.9 ± 2.5 2.9 ± 2.6
Control 1.5 ± 0.9 2.9 ± 1.4 1.5 ± 1.1
Percentages of CD25+ CD4+ T cells at baseline and after 3 cycles of scIL-2 therapy (week 24). The high dose IL-2 produced the greatest increase in 
CD25 percentages after scIL-2 administration. The high group had 4, the low group has 5 and none had 3.Journal of Translational Medicine 2007, 5:9 http://www.translational-medicine.com/content/5/1/9
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patients indicates that the starting level of apoptosis
reflects long term outcome to therapy and that the level of
CD8 T cell death is independent of viral load.
IL-2 is known as the consummate T cell growth factor;
however, IL-2 not only enhances proliferation and sur-
vival of T cells, it can also signal death in susceptible cell
populations. We suggest that the activated CD38+ DR+
population, which dies after acute administration of IL-2,
is indicative of this type of response to IL-2 in vivo. Since
CD8+ T cells do not upregulate CD25, it is likely they
respond to IL-2 via binding to CD122, (B chain IL-2R),
which at the time of these studies was not commercially
available. Of importance is that we saw no increase in
CD4+T cell death, even though there was CD38+ DR+ acti-
vation marker upregulation in the treated people at Day 5
of the scIL-2 cycle. This is in contrast to the conclusions of
another report; however, the data in that manuscript also
clearly show more apoptosis in the activated CD8+ T cells
than the CD4+ T cells after scIL-2 administration at Day 5
[23]. We think that activation of T cells by IL-2 likely leads
to differential outcomes in CD4+ vs. CD8+ T cell subpopu-
lations. Recent data, which examined DNA turnover in
CD4+ and CD8+ T cell subsets of HIV-infected people after
long-term scIL-2 therapy, are supportive of this idea
because IL-2 therapy enhanced CD4+ T cell survival, but
not CD8+ T cell survival [4].
The mechanism responsible for enhanced normalization
of CD4 cell counts in those with less CD8+ T cell death is
unclear. It may be associated with a better overall CD4 cell
count at the beginning point in the low CD8+ T cell apop-
tosis group. The CD4 cell count nadir in this group was
about 100 cells/mm3 higher and the median was higher
than in the high CD8+ T cell apoptosis group, which is
consistent with our previous observations that a high level
Increase in CD25 Expression on CD4+ T Cells 5 Days after IL-2 Therapy Initiation Figure 1
Increase in CD25 Expression on CD4+ T Cells 5 Days after IL-2 Therapy Initiation. Histogram of a representative 
response of CD4+ and CD8+ T cells to scIL-2. Shown are staining of CD4+ and CD8+ T cells with CD25 at Day 0 and after 5 
days of self administered scIL-2. Only the CD4+T cells show an increase of CD25 after 5 days.
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CD4+ T Cells Respond to IL-2 by Up-regulating CD25 Expression 5 Days after Every Cycle Figure 2
CD4+ T Cells Respond to IL-2 by Up-regulating CD25 Expression 5 Days after Every Cycle. a and b. IL-2 induces 
more CD25 expression on CD4+ T cells. Values are percentage of (a) CD4+ or (b) CD8+ T cells which express CD25. Repre-
sentative low-dose recipient shown. Patient received scIL-2 on days 1–5, 65–69 and 121–125
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of CD8+ T cell apoptosis was correlated with fewer CD4+ T
cells [18].
Our interpretation of this data is that the amount of CD8+
T cell apoptosis at baseline indicates existing immune
activation to HIV antigens, which can continue in some
patients, even without detectable viremia [14-16]. CD8+ T
cells, therefore, get activated and die at an increased level
in some individuals. Even though CD4 cell count
increases in IL-2 treated patients, the amount of prolifera-
tion in the long term actually becomes reduced as shown
in two studies [3,4]. It has been suggested that prolifera-
tion, as measured by Ki67 staining, found in cells in the
SG2M phase of the cell cycle, is similar to measurements
of activation using CD38 and DR expression [27]. Hence,
the better long-term outcome in those with less apoptosis
might be due to less inherent activation of cells from these
patients [28,29]. In the one IL-2 long-term non-responder
patient studied by Kovacs, et al [4], the DNA turnover of
both CD4+ and CD8+ T cells remained high, even after 22
cycles of scIL-2, indicating that chronic activation in some
people is not relieved by IL-2 therapy. Of interest is that
this patient also had about a log10 more HIV RNA (32,873
copies/mL) than other patients. However, we saw no cor-
relation in our small study with viral load, which
remained undetectable or barely detectable throughout
the study [30]. We did not have access to information on
viral set point in most of the patients. Non-responders to
IL-2 also have more T cell activation at baseline as shown
by others [3,4], which could also be reflected by higher
levels of CD8+ T cell death. The underlying reason for this
is not clear, but could be related to inherent host differ-
ences or a "set point" of CD4 cell count, below which an
enhanced CD8+ T cell apoptosis is triggered.
Activation and death of CD8 T cells in a patient receiving  three cycles of high dose scIL-2 Figure 4
Activation and death of CD8 T cells in a patient 
receiving three cycles of high dose scIL-2. Dying CD8+ 
T cells are activated. Values are percentage of CD8+ T cells 
that are CD38+ DRHi (diamonds) or that bind Annexin V (cir-
cles). Patient received 7.5 MIU scIL-2 on days 1–5, 57–61 and 
114–118.
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Increase in CD38+DR+ CD8+ T Cells 5 Days after scIL-2 Therapy Initiation Figure 3
Increase in CD38+DR+ CD8+ T Cells 5 Days after scIL-2 Therapy Initiation. Cytograms of CD38 and DR expression 
on CD8+ T cells during a single cycle of scIL-2. Both the percentage of CD38DRbright cells increases as well as the MFI of CD38 
on the whole population. (CD38 MFI DAY 0 = 7.41, DAY 5 = 20.9, DAY 30 = 7.46)
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Table 6: Baseline Characteristics of HIV Patients in Study.
Annexin levels at baseline Low High Total
N 771 4
Age at randomization (years; mean) 35 37 36
Age at HIV diagnosis (year; mean) 33 33 33
Female (n) 22 4
Race
Black (n) 40 4
White (n) 12 3
Hispanic (n) 25 7
Likely mode of infection*:
Sexual contact, same sex (n) 34 7
Sexual contact, opposite sex (n) 4 3 7
Injection drug use(n) 13 4
CD4+ (cells/mm3; median) 619 590 605
CD4+ nadir (cells/mm3; median) 384 203 219
HIV RNA <500 copies/mL (n) 671 3
Time since first prescribed ART (months; median) 14 20 17
Hepatitis B co-infection (n) 24 6
Hepatitis B co-infection (n) 1** 1 2
Hepatitis serology unknown (n) 22 4
* Subjects reported more than one mode of infection.
** Subject co-infected with HBV and HCV.
Table 4: CD8 Annexin V Levels at Baseline and 6 Years.
% Annexin V levels
(mean ± SD)
Baseline (mean ± SD) 6 Years (mean ± SD)
CD4
(cells/mm3)
CD8
(cells/mm3)
CD4:CD8 Ratio CD4
(cells/mm3)
CD8
(cells/mm3)
CD4:CD8 Ratio
Low 2.2 ± 2.1 625 ± 221 967 ± 386 0.76 ± 0.4 1209 ± 164 915 ± 308 1.55 ± 0.9
High 17.0 ± 6.0 527 ± 132 1234 ± 660 0.56 ± 0.36 754 ± 320 1172 ± 456 0.76 ± 0.4
p-value p = 0.331 p = 0.374 p = 0.327 p = 0.001 p = 0.240 p = 0.038
CD4 values, CD8 values, and CD4:CD8 ratios were recorded at baseline and 6 years for the low and high apoptosis groups. At baseline, a 
parametric t test showed no significance between low and high CD8 apoptosis levels for CD4, CD8 or CD4:CD8 ratios. However, after 6 years, a 
significant difference was observed between the high and low annexin groups with respect to CD4 values and CD4:CD8 ratios with p values of ≥ 
0.001 and ≥ 0.037. CD8 was not significantly different at any time point.
Table 5: CD8 Annexin V Levels at Baseline and 6 Years.
% Annexin V levels
(mean ± SD)
CD4 (cells/mm3)C D 8 ( c e l l s / m m 3) CD4:CD8 Ratio
Baseline 6 YR P-value Baseline 6 YR P-value Baseline 6 YR P-value
Low 2.2 ± 2.1 625 ± 221 1209 ± 164 0.001 967 ± 386 915 ± 308 0.766 0.76 ± 0.4 1.55 ± 0.9 0.038
High 17.0 ± 6.0 527 ± 132 754 ± 320 0.098 1234 ± 660 1172 ± 456 0.728 0.56 ± 0.36 0.7 ± 0.34 0.215
A repeated measures ANOVA showed a significant difference in the low annexin group for CD4 values from baseline to year 6 with a p value of p 
≥ 0.001. The high annexin group CD4 values were not significant from baseline to year 6 with a p value of ≥ 0.098. CD8 values in both the low and 
high apoptosis groups were not significant for the baseline or 6 year analysis. The CD4:CD8 ratio for the low apoptosis group was significant with a 
p value of ≥ 0.038, but the ratio for the high apoptosis group was not significant (p ≥ 0.215) after 6 years.Journal of Translational Medicine 2007, 5:9 http://www.translational-medicine.com/content/5/1/9
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Another possible mechanism to account for the role of
CD8+ T cell apoptosis relates to what drives the prolifera-
tion of T cells. That is, homeostatic mechanisms, like that
driven by IL-7, are one way that T cell proliferation is
driven. By contrast, activation-induced proliferation is
another mechanism whereby T cells divide. We think it
likely that the predominant form of CD8 proliferation
occurring in those with high CD8+ T cell apoptosis is acti-
vation-induced, rather than homeostatic-driven prolifera-
tion, because death occurs mainly with activation induced
proliferation, not homeostatic driven proliferation [31].
This may account for the slightly higher CD8 cell counts
in those with high apoptosis both before and after IL-2
therapy. These individuals fail to normalize CD4 T cell
numbers because CD8 activation and death continues in
spite of attempts at CD4 cellular reconstitution.
Conclusion
These data suggest that examination of CD8+ T cell apop-
tosis might serve as an indirect measure of the ability to
respond to immunoreconstitution. Our longitudinal uni-
variate analyses showed that both age and annexin were
significant predictors of CD4 T cell numbers over time.
However, entry of race into the model, showed that
annexin lost it's independent relationship to CD4+ T cell
number over time. Examination of possible ethnic differ-
ences in response to immune reconstitution is therefore
also warranted.
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